Penserra Capital Management
BEAM icon

Penserra Capital Management’s Beam Therapeutics BEAM Stock Holding History

Penserra Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,548
Closed -$253K – 1254
2023
Q3 		$253K Buy
10,548
+2,793
+36% +$74.9K 0.01% 672
2023
Q2 		$247K Buy
7,755
+1,405
+22% +$45.6K ﹤0.01% 723
2023
Q1 		$194K Buy
6,350
+80
+1% +$3.16K ﹤0.01% 701
2022
Q4 		$245K Sell
6,270
-3,369
-35% -$151K 0.01% 642
2022
Q3 		$459K Buy
9,639
+6,863
+247% +$392K 0.01% 448
2022
Q2 		$107K Buy
2,776
+1,076
+63% +$42.8K ﹤0.01% 758
2022
Q1 		$97K Buy
+1,700
New +$112K ﹤0.01% 851
2021
Q4 		– Sell
-1,525
Closed -$132K – 1388
2021
Q3 		$132K Buy
1,525
+100
+7% +$10K ﹤0.01% 706
2021
Q2 		$183K Buy
1,425
+115
+9% +$9.16K ﹤0.01% 658
2021
Q1 		$104K Sell
1,310
-25
-2% -$2.38K ﹤0.01% 677
2020
Q4 		$108K Buy
+1,335
New +$65.7K ﹤0.01% 596

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Penserra Capital Management's BEAM Position: Q4 2023 in Review

Penserra Capital Management sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 10,548 shares — an estimated $253K sold.

Penserra Capital Management first reported a position in BEAM in Q4 2020 and held it in 11 quarters. The position peaked at $459K in Q3 2022. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

  • Penserra Capital Management reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 10,548 Beam Therapeutics shares in Q4 2023, an estimated $253K.
  • Penserra Capital Management first reported a position in Beam Therapeutics in Q4 2020 and held it in 11 quarters.
  • Penserra Capital Management's Beam Therapeutics position peaked at $459K in Q3 2022.
  • 185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.